Tempest Therapeutics (TPST)
0.76
-0.02 (2.56%)
Upcoming Events
Latest Headlines
Form 8-K Tempest Therapeutics, For: Sep 11
September 15, 2026 4:07 PM - SEC Filing
Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang
September 15, 2026 4:05 PM - StreetInsider
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 15, 2026 4:05 PM - StreetInsider
Tempest Therapeutics raises $2.5M in private placement
September 11, 2026 8:00 AM - StreetInsider
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026 8:00 AM - StreetInsider
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026 8:30 AM - StreetInsider
Form 8-K Tempest Therapeutics, For: Aug 18
August 24, 2026 4:43 PM - SEC Filing
Form S-1 Tempest Therapeutics,
August 21, 2026 4:47 PM - SEC Filing
Form DEFA14A Tempest Therapeutics,
August 18, 2026 4:31 PM - SEC Filing
Form 8-K Tempest Therapeutics, For: Aug 17
August 18, 2026 4:28 PM - SEC Filing
Form 10-Q Tempest Therapeutics, For: Jun 30
August 13, 2026 4:38 PM - SEC Filing
Form 8-K Tempest Therapeutics, For: Aug 13
August 13, 2026 4:37 PM - SEC Filing
Form 8-K Tempest Therapeutics, For: Aug 13
August 13, 2026 4:33 PM - SEC Filing
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026 4:25 PM - Globe NewsWire
Form DEFA14A Tempest Therapeutics,
July 28, 2026 4:56 PM - SEC Filing
Form 8-K Tempest Therapeutics, For: Jul 27
July 28, 2026 4:51 PM - SEC Filing
Form 8-K Tempest Therapeutics, For: Jul 17
July 22, 2026 4:05 PM - SEC Filing
Tempest Therapeutics partners with Senlang on in vivo CAR-T candidate
July 21, 2026 7:02 AM - StreetInsider
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026 7:00 AM - StreetInsider
Form DEF 14A Tempest Therapeutics, For: Jul 27
July 17, 2026 4:32 PM - SEC Filing
Tempest Therapeutics plans in vivo CAR-T trial for late 2026
July 15, 2026 7:01 AM - StreetInsider
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026 7:00 AM - StreetInsider
Form 424B3 Tempest Therapeutics,
July 8, 2026 4:06 PM - SEC Filing
Form EFFECT Tempest Therapeutics,
July 8, 2026 6:03 AM - SEC Filing
Form PRE 14A Tempest Therapeutics, For: Jul 27
July 7, 2026 5:28 PM - SEC Filing
Tempest Therapeutics (TPST) files for 2.43M share offering by selling stockholders
June 26, 2026 4:05 PM - StreetInsider
Form S-3 Tempest Therapeutics,
June 26, 2026 4:03 PM - SEC Filing
Form 4 Tempest Therapeutics, For: Mar 24 Filed by: Angel Matthew
June 23, 2026 4:56 PM - SEC Filing
Form 8-K Tempest Therapeutics, For: Jun 18
June 23, 2026 6:04 AM - SEC Filing
Form D Tempest Therapeutics,
June 23, 2026 6:03 AM - SEC Filing
Full Article List
